|
Amoxicillin oral powder for suspension was recently added to the FDA drug shortage list due to increased demand. FDA is working with drug manufacturers to address amoxicillin oral suspension shortages. The FDA has also received requests for clarification about preparation of compounded versions of those products from FDA-approved tablets and capsules.
The FDA issued an immediately in effect guidance on the preparation of beta-lactam oral antibiotic suspension products that appear on FDA’s drug shortage list by a licensed pharmacist in a state-licensed pharmacy or federal facility. The guidance describes steps to reduce the risk of cross-contamination between these and other products.
Amoxicillin is a beta-lactam drug, and compounding this drug in an environment without appropriate safety measures could lead to cross-contamination of other drug products. Beta-lactam drugs can cause life-threatening allergic reactions in some patients.
At the November 17 business meeting, PQAC commissioners voted to revise two meeting dates for 2023. Please, mark your calendars for the proposed business meetings for 2023. Meetings will be hybrid meetings (Zoom ID# 882 5600 1236 / venue TBD). All business meetings begin at 9 a.m. via Zoom.
♦ January 12-13
♦ March 2-3 NEW DATE
♦ May 4-5
♦ June 15-16 NEW DATE
♦ August 24-25
♦ October 19-20
♦ December 14-15
*meetings subject to change
Please be advised, the legislative subcommittee meeting scheduled for December 2 has been canceled. The next legislative subcommittee meeting is scheduled for Friday, January 6, from 12-1 p.m.
The regular 2023 session of the Washington State Legislative Session begins January 9. PQAC will hold weekly updates each Friday beginning at noon during the legislative session.
Read what's been happening in Washington State pharmacy news in the fourth quarter 2022 National Pharmacy Compliance News. You may find previous editions on the NABP Washington State newsletter here.
|
